Neurocrine CSO settles RSUs, 2,248 shares withheld

Neurocrine Biosciences reports that Chief Scientific Officer Jude Onyia settled restricted stock units on November 29, 2025, receiving 4,426 shares of common stock.

Rhea-AI Filing Summary

Neurocrine Biosciences reports that Chief Scientific Officer Jude Onyia settled restricted stock units on November 29, 2025, receiving 4,426 shares of common stock. To satisfy tax obligations, 2,248 shares were withheld at $152.16 per share, and no shares were sold. Following these transactions, Onyia directly holds 15,881 common shares.

Insider Trade Summary

4,426 shares exercised/converted

Exercise 3 txns

Insider Onyia Jude

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	4,426	$0.00	$0.00
Exercise	Common Stock	4,426	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	2,248	$152.16	$342K

Holdings After Transaction: Restricted Stock Unit — 0 contracts (Direct); Common Stock — 15,881 shares (Direct)

Footnotes (3)

1. F1. Shares withheld by Neurocrine Biosciences, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.
2. F2. Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock.
3. F3. This RSU was granted to the Reporting Person on November 29, 2021. In accordance with the terms of the RSU, the award vested as to 4,425 shares on November 29, 2022, vested as to 4,425 shares on November 29, 2023, vested as to 4,426 shares on November 29, 2024, and vested as to 4,426 shares on November 29, 2025, subject to the terms and conditions of the award.

Key Figures

RSU shares vested: 4,426 shares Shares withheld for taxes: 2,248 shares Withholding price per share: $152.16 per share +4 more

7 metrics

RSU shares vested 4,426 shares Restricted stock units settling into common stock on November 29, 2025

Shares withheld for taxes 2,248 shares Common shares withheld to satisfy tax withholding requirements on RSU vesting

Withholding price per share $152.16 per share Value used for tax-withholding disposition of 2,248 common shares

Post-transaction holdings 15,881 shares Direct common stock holdings of Jude Onyia after the reported transactions

RSU grant date November 29, 2021 Grant date for the restricted stock unit award to the reporting person

2022 RSU vesting 4,425 shares Portion of the RSU award that vested on November 29, 2022

2023 RSU vesting 4,425 shares Portion of the RSU award that vested on November 29, 2023

Key Terms

Restricted Stock Unit, tax withholding requirements, contingent right, vested

4 terms

Restricted Stock Unit financial

"Shares withheld by Neurocrine Biosciences, Inc. to satisfy tax withholding requirements on vesting of restricted stock units (RSU)."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

tax withholding requirements financial

"Shares withheld by Neurocrine Biosciences, Inc. to satisfy tax withholding requirements on vesting of restricted stock units."

contingent right financial

"Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock."

vested financial

"In accordance with the terms of the RSU, the award vested as to 4,426 shares on November 29, 2025."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NBIX Chief Scientific Officer Jude Onyia report in this insider filing?

Jude Onyia reported RSU vesting that delivered 4,426 common shares on November 29, 2025. As part of the settlement, 2,248 shares were withheld to cover tax obligations, and no shares were sold in the market.

How many Neurocrine Biosciences (NBIX) shares were withheld for taxes?

The filing shows 2,248 common shares were withheld to satisfy tax withholding requirements. These shares were valued at $152.16 per share, and the footnote clarifies they were not sold but retained by the company for tax payment.

How many NBIX shares does Jude Onyia hold after the RSU vesting?

After the reported transactions, Jude Onyia directly holds 15,881 shares of Neurocrine Biosciences common stock. This post-transaction holding reflects the RSU settlement and related tax-withholding disposition reported in the filing.

What RSU grant and vesting schedule is disclosed for NBIX’s Chief Scientific Officer?

The RSU grant was made on November 29, 2021. It vested as to 4,425 shares on November 29, 2022, 4,425 shares on November 29, 2023, 4,426 shares on November 29, 2024, and 4,426 shares on November 29, 2025.

Did NBIX insider Jude Onyia sell any shares in this Form 4 transaction?

The footnote explicitly states that no shares were sold. Instead, 2,248 shares were withheld by Neurocrine Biosciences to satisfy tax withholding requirements related to the vesting of restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/02/2025 - 05:14 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Onyia Jude

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/29/2025		M		4,426	A	$0	18,129	D
Common Stock	11/29/2025		F		2,248(1)	D	$152.16	15,881	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(2)	11/29/2025		M			4,426	(3)	(3)	Common Stock	4,426	$0	0	D

Explanation of Responses:

1. Shares withheld by Neurocrine Biosciences, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

2. Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock.

3. This RSU was granted to the Reporting Person on November 29, 2021. In accordance with the terms of the RSU, the award vested as to 4,425 shares on November 29, 2022, vested as to 4,425 shares on November 29, 2023, vested as to 4,426 shares on November 29, 2024, and vested as to 4,426 shares on November 29, 2025, subject to the terms and conditions of the award.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	12/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.